HTGF closes seed funding for Lipocalyx

The investment will allow Lipocalyx to develop transfection reagants for siRNA based on innovative polymers.

GoodVent has known the founders of Lipocalyx for severak years and was also convinced by Lipocalyx's partnership with chemical company Chiroblock.
HTGF believes that Lipocalyx's products can be applied in an attractive niche market where there is significant demand for innovative solutions.

Company
Lipocalyx is a developer of transfection reagents for siRNA based on innovative polymers. The company is expecting to receive initial test results in Spring 2012.

People
Mehran Rafigh worked on the investment for High-Tech-Gründerfonds and Beate Bettecken is investment manager at GoodVent.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Now researching
• Germany